Clinical Trials
29 trialsNCT02354547 2026-05-08
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SynerGene Therapeutics, Inc.
Phase 1 Suspended
NCT05421897 2026-01-29
RAPID
Children's Hospital Los Angeles
Phase 1 Active not recruiting
NCT07365241 2026-01-26
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Not yet recruiting
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT04947501 2025-08-05
A Study of N9 Chemotherapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT03709680 2025-01-14
Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors
Pfizer
Phase 2 Active not recruiting
NCT00477282 2020-03-12
Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer
BioNumerik Pharmaceuticals, Inc.
Phase 3 Completed
NCT02500459 2019-03-01
Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection
Case Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT00361803 2017-11-17
Topotecan Pharmacokinetic Characterization Study
GlaxoSmithKline
Phase 1 Completed
NCT00483860 2017-11-13
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
GlaxoSmithKline
Phase 1 Completed
NCT00117013 2017-07-02
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00553189 2017-07-02
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00061308 2017-06-09
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00422682 2016-06-10
A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT01683149 2016-03-04
Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01840943 2015-12-23
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Xian-Janssen Pharmaceutical Ltd.
Phase 3 Terminated
NCT00770536 2015-09-29
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
Phase 1 Completed
NCT00382733 2013-07-22
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
Accelerated Community Oncology Research Network
Phase 1/2 Completed
NCT00250094 2011-09-07
Clinical Benefit of Topoisomerase Downregulation
New Mexico Cancer Research Alliance
Phase 1 Completed
NCT00429559 2011-07-22
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Hellenic Oncology Research Group
Phase 1/2 Completed
NCT00193583 2011-05-04
Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00397293 2010-08-24
Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer
Ascenta Therapeutics
Phase 1/2 Completed
NCT00320983 2010-01-07
Study of Adjuvant Topotecan and Cisplatin With Concurrent Radiation Therapy for Advanced Cervical Cancer
University of New Mexico
Phase 1 Completed
NCT00412503 2009-08-07
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT00888810 2009-04-28
TOPO-LAPA
Centre Francois Baclesse
Phase 2 Terminated
NCT00193570 2009-01-23
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00135135 2008-06-03
Therapy for Children With Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00006199 2005-06-24
Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)
National Center for Research Resources (NCRR)
Phase 1 Unknown